Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Audentes Therapeutics, Inc.BOLD · Entity 122788 | Senior VP & Chief Med Officer | June 05, 2019 | June 07, 2019 |
| Taysha Gene Therapies, Inc.TSHA · Entity 4549 | CMO and Head of R&D | July 05, 2022 | July 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Audentes Therapeutics, Inc.
Report date June 05, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,479 |
Reported balance
After 2019-06-05 transaction · row 1
1 source rowRow 1 · 2019-06-05 · Tax withholding · Disposed 757 · Balance 17,479 F1: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes.
Taysha Gene Therapies, Inc.
Report date July 05, 2022 · Filed July 07, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 530,589 |
Ending reported balance
After 2022-07-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-07-05 · Sale · Disposed 3,905 · Balance 539,545 F1: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3). Row 2 · 2022-07-06 · Sale · Disposed 8,956 · Balance 530,589 F1: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $4.00, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $4.00, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 26, 2018 Filed Mar 28, 2018 21:12 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 1,900 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-18-022004 · doc4.xml · derivative · entry 5 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,970 Underlying: Common Stock · 1,900 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 21:12 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 1,900 | $30.00 | $57,000.00 |
DisclosureSEC source: 0001209191-18-022004 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 21:12 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 1,900 | $0.79 | $1,501.00 |
DisclosureSEC source: 0001209191-18-022004 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-17-063856 · doc4.xml · derivative · entry 5 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,870 Underlying: Common Stock · 8,000 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 1,230 | $28.98 | $35,650.57 |
DisclosureSEC source: 0001209191-17-063856 · doc4.xml · nonDerivative · entry 4 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $28.95 and the highest price at which shares were sold was $29.04. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 1,230 | $0.79 | $971.70 |
DisclosureSEC source: 0001209191-17-063856 · doc4.xml · nonDerivative · entry 3 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 6,770 | $28.45 | $192,613.27 |
DisclosureSEC source: 0001209191-17-063856 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $27.93 and the highest price at which shares were sold was $28.91. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 16:00 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 6,770 | $0.79 | $5,348.30 |
DisclosureSEC source: 0001209191-17-063856 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 16, 2017 Filed Nov 17, 2017 17:07 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $27.39 | $0.00 |
DisclosureSEC source: 0001209191-17-061546 · doc4.xml · derivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-11-16 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning December 16, 2017, with 100% of the total shares vested and exercisable on November 16, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 17:55 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-17-051077 · doc4.xml · derivative · entry 3 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,870 Underlying: Common Stock · 8,000 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 17:55 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 8,000 | $21.44 | $171,480.80 |
DisclosureSEC source: 0001209191-17-051077 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 01, 2017 Filed Sep 1, 2017 17:55 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | Exercise / conversionCommon Stock | 8,000 | $0.79 | $6,320.00 |
DisclosureSEC source: 0001209191-17-051077 · doc4.xml · nonDerivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 29, 2017 Filed Mar 29, 2018 20:23 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 7,800 | $30.03 | $234,195.00 |
DisclosureSEC source: 0001209191-18-022169 · doc4.xml · nonDerivative · entry 2 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. The lowest price at which shares were sold was $30.00 and the highest price at which shares were sold was $30.16. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 27, 2017 Filed Mar 28, 2018 21:12 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | SaleCommon Stock | 300 | $30.00 | $9,000.00 |
DisclosureSEC source: 0001209191-18-022004 · doc4.xml · nonDerivative · entry 4 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 25, 2017 Filed Jan 27, 2017 18:10 UTC | Audentes Therapeutics, Inc. BOLD · Entity 122788 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $15.26 | $0.00 |
DisclosureSEC source: 0001209191-17-005999 · doc4.xml · derivative · entry 1 PRASAD SUYASH · CIK 0001679129 · Senior VP & Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2027-01-25 F1 · derivative.exercise_date: The option vests as to 2.0833% of the total shares monthly, beginning February 25, 2017, with 100% of the total shares vested and exercisable on January 25, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.